SCHEMBL2276388

SCHEMBL2276388

CCCOc1ccccn1.O=C(O)[Zn]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GRM2 Q14416 1/20 0.41
KMT2A Q03164 1/20 0.41
PSMB5 P28074 1/20 0.40
MAPK8 P45983 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
P4HTM Q9NXG6 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
BRD9 Q9H8M2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271442 0.89 TSHR (0.46) TSHRLMNAALDH1A1GRM2KMT2A
SCHEMBL29582311 0.88 NPC1 (0.44) TSHRLMNAALDH1A1CYP1A2SMN1; SMN2
SCHEMBL1268914 0.88 NPC1 (0.44) TSHRLMNAALDH1A1CYP1A2SMN1; SMN2
Ammonia Solution, Strong SCHEMBL7212028 0.86 NPC1 (0.43) TSHRLMNAALDH1A1CYP1A2SMN1; SMN2
SCHEMBL2268679 0.79 LMNA (0.44) TSHRLMNAALDH1A1CYP1A2SMN1; SMN2
SCHEMBL29379587 0.78 CYP2C19 (0.56) TSHRLMNAALDH1A1CYP1A2NPC1
SCHEMBL6803 0.78 CYP2C19 (0.56) TSHRLMNAALDH1A1CYP1A2NPC1
SCHEMBL5517724 0.77 LMNA (0.50) TSHRLMNAALDH1A1SMN1; SMN2NPC1
SCHEMBL423447 0.77 CYP2D6 (0.50) TSHRLMNACYP1A2SMN1; SMN2NPC1
SCHEMBL5515476 0.76 LTB4R (0.54) ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S C/O NOVI A/S, NIELS JERNES VEJ 10 (DK) 2006-07-06 US disclosed
EP-1307189-B1 USE OF HYDROXYETHYLRUTOSIDES FOR TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2006-05-10 EP disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol CHIA, MAVS, C1QBP TSHR 4733/4885LMNA 2370/4885ALDH1A1 1674/4885
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP TSHR 3718/4885LMNA 4008/4885ALDH1A1 1900/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP TSHR 3718/4885LMNA 4008/4885ALDH1A1 1900/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP TSHR 4733/4885LMNA 2370/4885ALDH1A1 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.